Early Drug Discovery Unit (EDDU) is specialized in the early stages of drug discovery, combining academic research with technology transfer to the chemical, pharmaceutical and biotechnology industries. We are a multidisciplinary team dedicated to developing new therapeutic solutions for a wide range of diseases.
Our goal is to collaborate with companies, research centers, and universities, as well as to develop internal projects, to translate cutting-edge research and approaches in the early stages of drug discovery into new drug candidates, bridging the gap between academic research and private sector capabilities.
We have unique expertise and technological capabilities in the initial steps of any drug discovery program: assessment of the therapeutic target’s “druggability,” development of screening assays,identification of new hits both computationally and experimentally, hit validation using biophysical techniques, medicinal chemistry for hit-to-lead processes and lead optimization, identification and synthesis of metabolites, guidance on intellectual property, development of new synthetic routes, andstructural chemical characterization.
We have a high level of expertise in some emerging modalities in drug discovery, such as targeted protein degradation (e.g., PROTACs and molecular glues) or the development of allosteric modulators.
We have an extensive track record in several aspects of active pharmaceutical ingredients (API)synthesis and analysis (e.g., identification, isolation, synthesis and characterisation of impurities and degradation products, route scouting, scale-up, analytical services, etc).
EDDU has been awarded the prestigious “TECNIO” seal by the Government of Catalonia, through ACCIÓ. This certification recognizes entities with proven capacity for developing and transferring technology from academia to the productive sector.
In the poster we will report services, collaborators, industrial doctorates, patents, etc. of the group.
